05-12-2025 19:25 via medpagetoday.com

First CAR T-Cell Therapy for Marginal Zone Lymphoma Gets FDA Green Light

(MedPage Today) -- Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi).
Approval was supported by findings from the TRANSCEND FL trial and stipulates...

Watch Out for Bleeding in These Cancer Patients on Extended Anticoagulation

Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years

FDA Opens Safety Review of Injectable RSV Drugs Approved for Babies and Toddlers

ACIP Chair's Hot Mic; Don't Deny COVID Vax Deaths; Abortion Drug Study Stalled

ACIP Chair's Hot Mic; Don't Deny COVID Vax Deaths; Abortion Drug Review Stalled

Phase I Vaccine Trial Shows Promise for Preventing Triple-Negative Breast Cancer

AI Model Improves Prediction of Early and Late Breast Cancer Recurrence

COVID Vax Death Probe Expands; Eggs Recalled; Med School Enrollment Up

Real-World Outcomes Favor Standard Care in HER2-Positive Metastatic Breast Cancer

Number of Hospitals Equipped to Handle Pediatric Cases on the Decline

The world is losing immunity to superbugs, but we can rebuild it

Explainer: Chagas disease spreads to richer countries

Ketamine Not a Better Anesthetic for Intubation of Critically Ill Patients

Energy Drinks Blamed for Man's Severe High Blood Pressure, Stroke

Desktop versie

First CAR T-Cell Therapy for Marginal Zone Lymphoma Gets FDA Green Light

Medical Industry news